We want to boost your innovative idea by joining forces and supporting your hypothesis validation. No strings attached in terms of IP and publishing since IP rights stay with you/your organisation and you are free to publish the results. This could be your start to an exciting drug discovery journey, so together, we can fuel the next generation of life-saving science and technologies.
Based in Denmark, our company started small as well, and today we are more than 50,000 people across the globe. We are discovering, developing and co-creating solutions to healthcare challenges for people living with diabetes, obesity, cardiovascular disease, NASH, chronic kidney disease and rare blood and endocrine disorders. Treatments and patient care have come a long way, and together, we can continue driving change to improve the lives of patients.
That’s why we hope you will join us in our call for applications below.
If you have any questions, please send an email to science2medicine@novonordisk.com.
Are you interested to take your scientific idea to the next level for the benefit of patients across the globe?
Scroll down and send us your application and innovative proposal that could lead to novel treatments for patients with diabetes, other cardiometabolic diseases and, rare haematology or endocrine disorders.
Who? We are looking for you, the scientist...
What? We are looking for innovative ideas on novel biology/pathways, drug targets, therapeutic approaches and enabling technologies that could improve treatments in our core disease focus and adjacent therapeutic areas.
We encourage applicants to submit their proposals as soon as possible, since applications will be evaluated on a rolling basis.
We aim to make the application/evaluation process as straightforward and quick as possible (<1 month). No lengthy proposals are required, 1-2 pages describing the idea and the experimental plan for validation are sufficient.
A panel of Novo Nordisk experts will review applications regularly and make the decision on a potential funding/partnership opportunity. Evaluation criteria include scientific novelty, potential therapeutic impact and robustness of experimental plan (“killer experiments”). Applicants may be invited to present/discuss their proposal if further clarification is needed.
We will discuss a standard statement of work/research collaboration agreement. Again, IP rights stay with you/your organisation and you are free to publish.
If your proposal is approved, Novo Nordisk will fund key experiments performed in your laboratory to validate your translational idea.
During the process, Novo Nordisk experts will be available for feedback and advice, and you will have access to Novo Nordisk open innovation resources.
After 6-9 months of hard work, you will present your results to Novo Nordisk experts and receive feedback. If both parties agree, we would love to discuss follow-up funding and long-term partnership options.